ð¿ñð°ð²ð¾ - Open Access .click

Results 41 to 50 of about 6,247,377 (254)

Ð•Ð’ÐÐ›Ð£ÐÐ¦Ð˜ÐˆÐ ÐÐ ÐŸÐ ÐžÐ“Ð ÐÐœÐ˜Ð¢Ð• Ð—Ð ÐŸÐ Ð•Ð’Ð•ÐÐ¦Ð˜ÐˆÐ ÐÐ ÐœÐÐ›Ð˜Ð“ÐÐ˜ ÐÐ•ÐžÐŸÐ›ÐÐ—ÐœÐ˜ Ð’Ðž Ð Ð•ÐŸÐ£Ð‘Ð›Ð˜ÐšÐ ÐœÐÐšÐ•Ð”ÐžÐÐ˜ÐˆÐ (2005-2015) [PDF]

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source

Measurement of D0, D+, D*+ and D s + production in Pb-Pb collisions at s N N = 5.02 $$ \sqrt{{\mathrm{s}}_{\mathrm{NN}}}=5.02 $$ TeV

Journal of High Energy Physics, 2018
We report measurements of the production of prompt D0, D+, D*+ and D s + mesons in Pb–Pb collisions at the centre-of-mass energy per nucleon-nucleon pair s N N = 5.02 $$ \sqrt{s_{\mathrm{NN}}}=5.02 $$ TeV, in the centrality classes 0–10%, 30–50% and 60 ...
The ALICE collaboration +1003 more
doaj +1 more source

ÐÐÐ¢Ð˜ÐœÐ˜ÐšÐ ÐžÐ‘ÐÐ Ð Ð•Ð—Ð˜Ð¡Ð¢Ð•ÐÐ¦Ð˜ÐˆÐ (ÐÐœÐ ) Ð’Ðž Ð•Ð’Ð ÐžÐŸÐ Ð˜ Ð‘ÐÐ›ÐšÐÐÐ¡ÐšÐ˜ÐžÐ¢ Ð Ð•Ð“Ð˜ÐžÐ – ÐŸÐ Ð•Ð“Ð›Ð•Ð” ÐÐ Ð¡Ð•Ð“ÐÐ¨ÐÐÐ¢Ð Ð¡ÐžÐ¡Ð¢ÐžÐˆÐ‘Ð [PDF]

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy +5 more
wiley +1 more source

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata +9 more
wiley +1 more source

Ob etimologii i semantike termina voršud/vožšud [On the Etymology and Semantics of the Term voršud/vožšud]; pp. 276-282 [PDF]

Linguistica Uralica, 2014
The paper deals with the concept of Ð²Ð¾ÑÑÑÐ´/Ð²Ð¾Ð¶ÑÑÐ´ in the Udmurt language, which used to serve as a theonym for one of the traditional deities. The word was preserved by Udmurt local groups living in a foreign-language environment.
Nadežda Šutova
doaj +1 more source

Ð•Ð¤Ð•ÐšÐ¢Ð˜ ÐÐ CYP3A4 Ð“Ð•ÐÐ•Ð¢Ð¡ÐšÐ˜ ÐŸÐžÐ›Ð˜ÐœÐžÐ Ð¤Ð˜Ð—ÐÐœ Ð’Ð Ð— ÐŸÐžÐ¡Ð¢ÐžÐŸÐ•Ð ÐÐ¢Ð˜Ð’ÐÐÐ¢Ð ÐŸÐžÐ¢Ð ÐžÐ¨Ð£Ð’ÐÐ§ÐšÐ ÐÐ Ð¤Ð•ÐÐ¢ÐÐÐ˜Ð› ÐŸÐ Ð˜ Ð¢Ð Ð•Ð¢ÐœÐÐ ÐÐ ÐŸÐžÐ¡Ð¢ÐžÐŸÐ•Ð ÐÐ¢Ð˜Ð’ÐÐÐ¢Ð Ð‘ÐžÐ›ÐšÐ [PDF]

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson +20 more
wiley +1 more source

astrophysics
linguistics
zoology

philology
extended supersymmetry